Article Text

Download PDFPDF

PS2:27 Antibodies to carbamylated vimentin in patients with systemic lupus erythematosus are associated with renal involvenment
  1. FR Spinelli,
  2. T Colasanti,
  3. S Truglia,
  4. A Pecani,
  5. F Ceccarelli,
  6. F Miranda,
  7. E Moscarelli,
  8. R Mancini,
  9. C Perricone,
  10. C Alessandri,
  11. G Valesini and
  12. F Conti
  1. Sapienza Università di Roma, Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia, Rome, Italy


Vimentin is a cytoskeletal protein expressed by mesenchymal cells, including endothelial and renal tubular cells. Antibodies to vimentin were described in 10%–53% of patients with Systemic Lupus Erythematosus (SLE). Vimentin has been proposed as a target of the in situ immune response in lupus nephritis. Post-translational modifications increase the immunogenicity of vimentin, as demonstrated by the detection of anti-modified-vimentin antibodies in rheumatoid arthritis. Carbamylation is a non-enzymatic post-translational modification (addition of a cyanate group on lysine and arginine residues), which has been linked to NETosis. The role of carbamylated vimentin (Car-Vim) as an antigenic target in SLE has not been evaluated yet.

Aim of the study was to assess the prevalence of anti-Car-VIm and to investigate any association with clinical and serological features in SLE patients.

We enrolled SLE diagnosed according to 1997 ACR criteria. Clinical features, autoantibodies profile and disease activity – according to SLEDAI 2K – were collected. Patients’ sera were tested for anti- Car-Vim by a home-made enzyme-linked immunoassay. Data were expressed as mean ±standard deviation or median (interquartile range) when appropriate. Mann-Whitney and Chi square test were applied to investigate differences in anti-carbamylated vimentin prevalence and serum levels. P value<0.05 was considered statistically significant.

We enrolled 109 SLE patients (102F:7M, mean age 39.4±12.6 years, mean disease duration 10.5±9.5 years, mean SLEDAI 2K 5±5.5). Table 1 summarises the main clinical and serological features. Overall, 30/109 patients (27.5%) were positive for anti-Car-Vim. The prevalence of anti-Car-Vim was significantly higher in patients with lupus nephritis (18/44) compared to those without (12/66) (41.8% vs 18.2%, p=0.006); moreover, anti-Car-Vim serum levels were significantly higher in patients with lupus nephritis [2561 (1783) OD] compared to those without [1970 (1123) OD; p=0.0178]. No difference was found in prevalence or titre of anti-Car-Vim in presence/absence of other clinical or serological manifestations. No correlation between anti-Car-Vim serum levels and SLEDAI 2K was found.

Higher prevalence and serum levels of anti-carbamylated vimentin antibodies in patients with lupus nephritis confirm the role of vimentin as a target of the immune response in glomerulonephritis and suggest their possible role as a biomarker of kidney involvement in SLE.

Abstract PS2:27 Table 1

Clinical and serological feature of the patients at the time of enrolment

  • Anti-Carbamylated Vimentin
  • Lupus Nephritis
  • Posttransaltional Modification

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.